TY - JOUR
T1 - Current unmet needs and potential solutions to uncontrolled asthma
AU - Busse, William W.
AU - Kraft, Monica
N1 - Funding Information:
Support statement: This publication was funded by Novartis Pharma, Basel, Switzerland. Novartis did not have any input into the content. Medical writing support for the development of this manuscript, under the direction of the authors, was provided by Ellen Maxwell, PhD, of Ashfield MedComms, an Ashfield Health company and funded by Novartis. This publication was written in accordance with Good Publications Practice (GPP3) guidelines (http:// www.ismpp.org/gpp3). Funding information for this article has been deposited with the Crossref Funder Registry.
Funding Information:
Conflict of interest: W.W. Busse reports consultant fees from AstraZeneca, Genentech, GSK, Novartis, Regeneron Pharmaceuticals Inc., and Sanofi, outside the submitted work. M. Kraft reports grants from NIH, Sanofi, ALA, Chiesi and AstraZeneca, consultant fees from Sanofi and AstraZeneca, and Chief Medical Officer fees from RaeSedo LLC, outside the submitted work.
Publisher Copyright:
© 2022, European Respiratory Society. All rights reserved.
PY - 2022/3/31
Y1 - 2022/3/31
N2 - Despite the availability of effective inhaled therapies, many patients with asthma have poor asthma control. Uncontrolled asthma presents a significant burden on the patient and society, and, for many, remains largely preventable. There are numerous reasons why a patient may remain uncontrolled despite access to therapies, including incorrect inhaler technique, poor adherence to treatment, oversight of triggers and suboptimal medical care. Shared decision-making, good patient–clinician communication, supported self-management, multidisciplinary patient education, new technology and risk stratification may all provide solutions to this major unmet need in asthma. Novel treatments such as biologics could benefit patients’ lives, while the investigations into biomarkers, non-Type 2 asthma, treatable traits and disease modification give an exciting glimpse into the future of asthma care.
AB - Despite the availability of effective inhaled therapies, many patients with asthma have poor asthma control. Uncontrolled asthma presents a significant burden on the patient and society, and, for many, remains largely preventable. There are numerous reasons why a patient may remain uncontrolled despite access to therapies, including incorrect inhaler technique, poor adherence to treatment, oversight of triggers and suboptimal medical care. Shared decision-making, good patient–clinician communication, supported self-management, multidisciplinary patient education, new technology and risk stratification may all provide solutions to this major unmet need in asthma. Novel treatments such as biologics could benefit patients’ lives, while the investigations into biomarkers, non-Type 2 asthma, treatable traits and disease modification give an exciting glimpse into the future of asthma care.
UR - http://www.scopus.com/inward/record.url?scp=85123816868&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123816868&partnerID=8YFLogxK
U2 - 10.1183/16000617.0176-2021
DO - 10.1183/16000617.0176-2021
M3 - Review article
C2 - 35082128
AN - SCOPUS:85123816868
SN - 0905-9180
VL - 31
JO - European Respiratory Review
JF - European Respiratory Review
IS - 163
M1 - 210176
ER -